Replies to post #198538 on Biotech Values

[zipjet]

>>CELG +10% of Revlimid patent settlement. (Big %move for a company with a market cap in the vicinity of $100B.)
© 2015 InvestorsHub.Com, Inc.

Some analyst showed the PV of the additional revenue as $2-3. So yes seems a big move. But then removing the uncertainty is also worth something.